These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 34562851)

  • 21. Computational prediction of the effect of mutations in the receptor-binding domain on the interaction between SARS-CoV-2 and human ACE2.
    Celik I; Khan A; Dwivany FM; Fatimawali ; Wei DQ; Tallei TE
    Mol Divers; 2022 Dec; 26(6):3309-3324. PubMed ID: 35138508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Computational redesign of Fab CC12.3 with substantially better predicted binding affinity to SARS-CoV-2 than human ACE2 receptor.
    Treewattanawong W; Sitthiyotha T; Chunsrivirot S
    Sci Rep; 2021 Nov; 11(1):22202. PubMed ID: 34772947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Computational prediction of the effect of amino acid changes on the binding affinity between SARS-CoV-2 spike RBD and human ACE2.
    Chen C; Boorla VS; Banerjee D; Chowdhury R; Cavener VS; Nissly RH; Gontu A; Boyle NR; Vandegrift K; Nair MS; Kuchipudi SV; Maranas CD
    Proc Natl Acad Sci U S A; 2021 Oct; 118(42):. PubMed ID: 34588290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
    Nayak SK
    Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain.
    Yang J; Zhang Z; Yang F; Zhang H; Wu H; Zhu F; Xue W
    Chem Biol Drug Des; 2021 Jul; 98(1):1-18. PubMed ID: 33894099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid Assessment of Binding Affinity of SARS-COV-2 Spike Protein to the Human Angiotensin-Converting Enzyme 2 Receptor and to Neutralizing Biomolecules Based on Computer Simulations.
    Buratto D; Saxena A; Ji Q; Yang G; Pantano S; Zonta F
    Front Immunol; 2021; 12():730099. PubMed ID: 34858396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution.
    Zahradník J; Marciano S; Shemesh M; Zoler E; Harari D; Chiaravalli J; Meyer B; Rudich Y; Li C; Marton I; Dym O; Elad N; Lewis MG; Andersen H; Gagne M; Seder RA; Douek DC; Schreiber G
    Nat Microbiol; 2021 Sep; 6(9):1188-1198. PubMed ID: 34400835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutations of SARS-CoV-2 RBD May Alter Its Molecular Structure to Improve Its Infection Efficiency.
    Alaofi AL; Shahid M
    Biomolecules; 2021 Aug; 11(9):. PubMed ID: 34572486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced binding of the N501Y-mutated SARS-CoV-2 spike protein to the human ACE2 receptor: insights from molecular dynamics simulations.
    Luan B; Wang H; Huynh T
    FEBS Lett; 2021 May; 595(10):1454-1461. PubMed ID: 33728680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Understanding the molecular interaction of SARS-CoV-2 spike mutants with ACE2 (angiotensin converting enzyme 2).
    Istifli ES; Netz PA; Sihoglu Tepe A; Sarikurkcu C; Tepe B
    J Biomol Struct Dyn; 2022; 40(23):12760-12771. PubMed ID: 34495817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2-Spike RBD Interface.
    Villoutreix BO; Calvez V; Marcelin AG; Khatib AM
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33567580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion.
    Augusto G; Mohsen MO; Zinkhan S; Liu X; Vogel M; Bachmann MF
    Allergy; 2022 Jan; 77(1):111-117. PubMed ID: 34453338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SARS-CoV-2 omicron RBD forms a weaker binding affinity to hACE2 compared to Delta RBD in
    Le HT; Tran LH; Phung HTT
    J Biomol Struct Dyn; 2024 May; 42(8):4087-4096. PubMed ID: 37345564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutations on RBD of SARS-CoV-2 Omicron variant result in stronger binding to human ACE2 receptor.
    Lupala CS; Ye Y; Chen H; Su XD; Liu H
    Biochem Biophys Res Commun; 2022 Jan; 590():34-41. PubMed ID: 34968782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Possible Link between Higher Transmissibility of Alpha, Kappa and Delta Variants of SARS-CoV-2 and Increased Structural Stability of Its Spike Protein and hACE2 Affinity.
    Kumar V; Singh J; Hasnain SE; Sundar D
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Receptor binding, immune escape, and protein stability direct the natural selection of SARS-CoV-2 variants.
    Upadhyay V; Lucas A; Panja S; Miyauchi R; Mallela KMG
    J Biol Chem; 2021 Oct; 297(4):101208. PubMed ID: 34543625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Double Mutation (L452R and E484Q) on the Binding Affinity of Monoclonal Antibodies (mAbs) against the RBD-A Target for Vaccine Development.
    Gupta D; Kumar M; Sharma P; Mohan T; Prakash A; Kumari R; Kaur P
    Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of a neutralizing antibody that recognizes a loop region adjacent to the receptor-binding interface of the SARS-CoV-2 spike receptor-binding domain.
    Anzai I; Fujita J; Ono C; Kosaka Y; Miyamoto Y; Shichinohe S; Takada K; Torii S; Taguwa S; Suzuki K; Makino F; Kajita T; Inoue T; Namba K; Watanabe T; Matsuura Y
    Microbiol Spectr; 2024 Apr; 12(4):e0365523. PubMed ID: 38415660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context.
    Tragni V; Preziusi F; Laera L; Onofrio A; Mercurio I; Todisco S; Volpicella M; De Grassi A; Pierri CL
    EPMA J; 2022 Mar; 13(1):149-175. PubMed ID: 35013687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.